The correction of post-transplant hyperlipidaemia warrants the judicious and timely use of pharmacological agents with dietary modification and exercise. Reduction in hyperlipidaemia may have some role in decreasing the incidence of chronic rejection of allografts. The awareness that the morbidity and mortality of atherosclerotic disease may be lowered by active intervention will result in a better quality of life for transplant recipients. In recipients of organ transplants, atherosclerotic vascular disease constitutes a major hurdle to long-term survival. In the general population, clinical trials, experimental, and epidemiological studies have effectively demonstrated the benefits of reducing lipids in arresting, or diminishing pre-existing coronary atherosclerotic lesions.' Measures to reduce plasma cholesterol are fundamental to the practice of preventative cardiology, and by corollary, should be the cornerstone of measures to reduce the continuing high morbidity and mortality in recipients of organ transplants.'
In recipients of organ transplants, atherosclerotic vascular disease constitutes a major hurdle to long-term survival. In the general population, clinical trials, experimental, and epidemiological studies have effectively demonstrated the benefits of reducing lipids in arresting, or diminishing pre-existing coronary atherosclerotic lesions.' Measures to reduce plasma cholesterol are fundamental to the practice of preventative cardiology, and by corollary, should be the cornerstone of measures to reduce the continuing high morbidity and mortality in recipients of organ transplants.'
A number of large-scale studies in both the normal population and 'at-risk' subjects have demonstrated the benefits of lowering cholesterol. Most recently, the West of Scotland trial has shown the beneficial effect of reducing hypercholesterolaemia in healthy men at high risk for coronary heart disease. 8 This was the latest in a series of clinical trials which essentially confirmed the result of previous studies, most notably, the Los Angeles Veterans Diet trial, the WHO Clofibrate trial, the Lipid Research Clinics Cholestyramine trial, and the Helsinki Heart trial. 9 The Scandinavian Simvastatin Survival study provided further evidence of the beneficial effects of reducing cholesterol -a 42% reduction in the risk of coronary death in simvastatin-treated subjects.'0
Immunosuppressive regimens comprising steroids, cyclosporin and FK506 (Prograf, tacrolimus) have significant diabetogenic properties." In addition, the great majority of transplant recipients have hypertension. These additional factors may alter the course of atherosclerosis, which is likely to be more aggressive than that of the general population.
The incidence of post-transplant hyperlipidaemia (PTHL) has varied from 22% to 54%, although some of this variation may be due to the lack of standardisation in reporting of the lipid levels. Vathsala et al'2 compared the effects of three different immunosuppressive protocols on hypercholesterolaemia in kidney transplant recipients; patients receiving Imuran-prednisolone had a 42.2% incidence versus 26 .3% in the cyclosporin-prednisolone group; in heart transplant recipients, total cholesterol was greater in patients receiving cyclosporin -prednisolone therapy versus patients receiving cyclosporinImuran therapy. '3 In our study of liver transplant recipients, PTHL was seen in 58%. More significantly, 37% of recipients had both post-transplant diabetes mellitus and hyperlipidaemia. 14 It can be assumed that at least 50% of transplant recipients will have significant abnormalities of serum lipids.
Decisions about treatment of PTHL must be based on multiple factors, such as the assessment of risk, extent of benefits, cost, side-effects of medications, and possible interactions of immunosuppressants with drugs used to lower serum lipids. Furthermore, the emerging role of hypercholesterolaemia as a risk factor for chronic graft rejection must also be taken into account when initiating therapy for PTHL.
Synopsis of proposed mechanisms HYPERLIPIDAEMIC EFFECTS OF STEROIDS
There is convincing evidence that long-term therapy with steroids increases both cholesterol and triglyceride levels. Steroids promote insulin resistance with a secondary hyperinsulinaemia and increase the hepatic secretion of very low density lipoproteins (VLDL). The latter effect is due to a reduction in lipoprotein lipase activity, and overproduction of triglycerides by the liver. 5 
HYPERLIPIDAEMIC EFFECTS OF CYCLOSPORIN AND FK506
A number of studies have shown that cyclosporin increases the total plasma cholesterol and triglyceride levels in the heart, liver, and kidney of transplant recipients. The mechanisms of its adverse effect on serum lipids is multifactorial. Cyclosporin may interfere with bile acid synthesis by inhibiting 26-hydroxylase (the first step in the side-chain oxidation of intermediates of the bile acid pathway), thereby limiting cholesterol degradation. It also decreases the uptake of low-density lipoprotein (LDL)-cholesterol, and may down-regulate 7indal the hepatocyte membrane LDL receptor.'6 Experimental studies have shown that cyclosporin stimulates cholesterol synthesis by increasing 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase activity, and also decreases the activity of lipoprotein lipase which reduces the clearance of VDLD and chylomicrons, resulting in hypertriglyceridaemia. ' Investigators have suggested the association of diabetes with increased free radical generation leading to the increased oxidation of LDL'4; increased rates of nonenzymatic glycosylation of LDL apolipoprotein B is thought to render LDL more susceptible to peroxidation"3 leading to atheroscferosis.
Studies have shown that meticulous control of diabetes will result in higher levels of HDL and lower levels of cholesterol due to the increased activity of lipoprotein lipase activity.36 However, in patients with NIDDM, there is a persistence of dyslipidaemia as insulin resistance continues to be a dominant factor despite treatment with insulin or sulfonylureas, however, this situation may change with the recent introduction of metformin in clinical practice. Patients with NIDDM frequently present with low levels of HDL, and as low levels of HDL seem to predict the early development of cardiovascular disease, efforts should be made to raise HDL levels. '7 The Diabetes Control and Complications Trial provided persuasive evidence that tight control of glucose with insulin in patients with IDDM markedly reduced the incidence of microvascular complications38; similar beneficial effects may be expected in the NIDDM patients. When instituting intensive insulin regimens for post-transplant diabetes mellitus, the adverse effects of an intensive insulin regimen such as weight gain and increase in hypoglycaemic episodes must be kept in mind. Furthermore, the atherogenic potential of 'overinsulinisation' has been a cause for concern; however, sufficient evidence does not exist to implicate insulin as a cardiovascular risk factor.'9 The goal should be to achieve near-normal glycaemia (glycohaemoglobin level no more than 1% above the upper normal limit) initially by diet 7indal and exercise therapy, followed by oral hypoglyaemic agents, and finally insulin regimens. Some beta-blockers and diuretics which tend to lower HDL levels should be avoided. 
Dietary modification
Transplant recipients must be encouraged to follow the American Heart Association Step-One Diet, aimed at restricting the intake of saturated fat and cholesterol. A regular exercise programme, cessation of smoking, control of diabetes, and hypertension should also be essential components of posttransplant management.52 The risk-benefit ratio of certain drugs, such as oral contraceptives, antidepressants, anti-acne drugs, beta-blockers, thiazides, and anti-infectives, must be carefully assessed as these may have an adverse effect on lipids.
EFFECT OF DIETARY SUPPLEMENTATION WITH FISH OIL ON SERUM LIPIDS
The importance of dietary modification to alter the immune response has come from experimental and clinical studies. Rat heart allografts showed significantly increased survival when fed n-3 polyunsaturated fatty acid,53 but some data pointed to the fact that improved graft survival was related to a decrease in the n-6 fatty acid content. 54 It is possible that the ratio of dietary n-31n-6 fatty acids may be more important than absolute levels of individual fatty acids. It was shown that the immunoregulatory effect of pretransplant blood transfusion was mediated by altering the essential fatty acid composition,55 and coronary atherosclerosis in the rat heart allograft model was slowed by administration of fish oil.56 Omega-3 fatty acids are postulated to exert their immunomodulatory effect by multiple mechanisms: inhibiting the effect of interleukin (IL)-1, tumour necrosis factor, altering histocompatability antigen (HLA-DR) expression, reducing vascular smooth muscle proliferation, and vascular permeability. 57 Reports have suggested that the administration of omega-3 fatty acids in the form of fish oil have improved renal haemodynamics and serum lipids in recipients of renal transplants. Furthermore, patients taking supplemental fish oil had better control of post-transplant hypertension, with fewer acute and chronic rejection episodes.58-68 However, most of these studies have been small and limited to a single centre. There is a strong case for a larger multicentre trial to define the role of fish oil supplementation in transplant recipients.
EFFECT OF DIETARY SUPPLEMENTATION WITH SOYA PROTEIN ON SERUM LIPIDS
A meta-analysis by Anderson et all9 showed that in 34 of 38 clinical studies, serum cholesterol levels were reduced to a greater extent in patients treated with soya protein. Those subjects who had moderate-to-severe hypercholesterolaemia had a greater benefit than those persons with mild elevations of serum cholesterol. However, this interpretation has not been accepted by all researchers, as some studies did not show a reduction in LDL, and the effect on persons with mild hypercholesterolaemia (200 mg/dl or less) was not significant.70 Indeed, the conclusion of the American Heart Association (1993, Diet-Heart Statement) was that the effect of soya protein intake on serum lipids in clinical trials was not convincing. Nevertheless, there are sufficient data in favour of the moderate use of soya protein as part of an overall balanced diet.
Lipid-lowering drugs for transplant recipients
The National Cholesterol Education Program suggested the use of cholestyramine and nicotinic acid as the first line of treatment for primary hypercholesterolaemia. Cholestyramine may interfere with the absorption of cyclosporin, however, it is not known whether the microemulsion form of cyclosporin (Neoral) may allow the concomitant use of cholestryamine. Furthermore, bile-acid-binding resins may cause constipation, sodium retention, and may increase triglycerides. Niacin was found to be effective in mixed hyperlipidaemias, but may cause multiple side-effects such as flushing, glucose intolerance, hyperuricaemia, and hepatotoxicity. Fibric acid derivatives such as gemfibrozil was found to be effective in renal transplant recipients by reducing the cholesterol/HDL ratio; however, it was not recommended for use in liver transplant recipients because it increased the incidence of biliary stones.7' The statins (HMG-CoA reductase inhibitors) are the most commonly used lipid-lowering agents in transplant recipients. Kasiske et aft2 used lovastatin in recipients of kidney transplants (receiving prednisone and Imuran) and showed that reductions in total and LDL-cholesterol levels were of the same magnitude as that reported in the treatment of primary hyperlipidaemias, but the increase in HDL was not significant. They did not find alterations in liver enzymes, or elevation of creatine kinase levels, although there was a significant increase of white blood cells, even when lovastatin was used in relatively low doses (20 mg/day). It is also alarming to note a high incidence of rhabdomyolysis in cardiac transplant recipients treated with cyclosporin and lovastatin,73 but not in recipients of other organs.
Yoshimura et aFl4 evaluated the effect of pravastatin (10 mg/day) and found that it was effective in reducing total cholesterol and LDL in renal transplant recipients; levels of HDL and triglycerides were unaffected with no adverse effect on the graft function or the creatine kinase levels. The effect of pravastatin was also evaluated in heart transplant recipients (receiving cyclosporin, prednisone, Imuran) in a randomised placebo-controlled study.75 Pravastatin was given in the dose of 20 mg/day and increased to 40 mg/day when tolerated. At the end of a year cholesterol levels were significantly lower and there was a reduced incidence of rejections in the pravastatin group. Of great interest were the findings that in the control group of patients, there was a significantly increased intimal thickness and intimal index as assessed by intra-coronary ultrasonography. From this study it seems that statins caused an increased state of immunosuppression, although the precise mechanisms can only be speculated at the present time. It has been postulated that HMG-CoA reductase inhibitors decrease antibody-dependent cellular cytotoxicity and natural killer cell function.76 Fluvastatin in recipients of renal transplants was seen to reduce total cholesterol by about 13%, LDL by about 22%, and Apo B by about 13% with no adverse effects on either cyclosporin levels, renal and liver function tests, or creatine kinase levels. 77 Massay et aft8 recently conducted a meta-analysis of 154 studies involving 3065 patients to compare the relative efficacy of antilipidaemic agents in patients with renal disease including recipients of renal transplants. Of the 29 study groups, 28 showed reduction in cholesterol, 24 in triglyceride levels, and eight showed reduction in LDL levels by dietary intervention. HMG-CoA reductase inhibitors were effective in reducing cholesterol and LDL in the majority of patients treated, but the reduction in triglyceride levels was not as effective. Interestingly, of the 14 patient groups who received fish oil, 12 groups showed a reduction in triglyceride levels. They concluded that low doses of statins were effective in lowering LDL; renal transplant recipients with high triglyceride levels and low HDL levels showed benefit with a fibric acid derivative.
The efficacy of all four HMG-CoA reductase inhibitors as monotherapy in lowering total cholesterol and LDL has been confirmed in numerous placebocontrolled trials. However, the comparative effects of these drugs have been difficult to evaluate because of multiple uncontrolled variables. Hsu et aFt9 reviewed the comparative safety and efficacy of fluvastatin, pravastatin, lovastatin, and simvastatin. They found that on a mg-per-mg basis, simvastatin was twice as potent as lovastatin and pravastatin; the hypocholesterolaemic effect of fluvastatin appeared to be 30% less than that of lovastatin. In posttransplant patients receiving cyclosporin, lovastatin and simvastatin were seen to be safe, but pravastatin was considered the drug of choice at higher dosages because of its lower incidence of side-effects such as myopathy. Combination therapy consisting of HMG-CoA reductase inhibitor and gemfibrozil was recommended for patients with secondary or severe combined hyperlipidaemia, although the combination of lovastatin -gemfibrozil was associated with the development of rhabdomyolysis. Clinically significant side-effects were rare, and drug withdrawal because of clinical or laboratory adverse reactions were comparable among the four agents.
There is a strong case for aggressive management of PTHL as investigations have suggested that a 1% reduction in total cholesterol decreases the risk for ischaemic heart disease by 2% in individuals with primary hyperlipidaemia.80 These data could be extrapolated to secondary hyperlipidaemia of transplant recipients. Risk assessment is important; lipid-lowering drugs should be one of the components of the overall strategy in reducing the incidence of cardiovascular disease. It is tempting to suggest the routine use of fish oil and soya protein in transplant recipients; however, evidence so far has come from only small studies.
Summary points * transplant recipients have a triple risk for cardiovascular accidents: hyperlipidaemia, hypertension, and post-transplant diabetes * correction of each of these factors will lead to a reduction of cardiovascular and neurovascular morbidity and mortality * at least 50% of all transplant recipients will have significant hyperlipidaemia * hypercholesterolaemia may also be a risk factor for chronic graft rejection * hyperlipidaemia may be organ specific; heart transplant patients are more susceptible than liver transplant recipients Box 4 Steroid-reducing regimens in PTHL Although dietary therapy to correct lipid abnormalities was recommended as the first line of treatment in these trials, lipid-lowering agents were also necessary in most patients.'02 A recently completed, controlled, and widely cited trial, in the general population convincingly demonstrated that reduction of hypercholesterolaemia by diet and pravastatin reduced the incidence of subjects undergoing myocardial re-vascularisation procedures, and also reduced the risk of cardiovascular mortality without increasing the risk of death from noncardiovascular causes. The subjects were asymptomatic (no previous myocardial infarction) men between 45-64 years, and had a mean total cholesterol of 272 mg/dl.8 Similar studies in post-transplant recipients are lacking; however, these results can be extrapolated to transplant recipients who have cholesterol levels in a similar range.
Some recent data also suggest that PTHL may be organ specific; liver transplant recipients have a lesser degree of hyperlipidaemia than recipients of renal or heart transplants.'0' In particular, coronary lesions from explanted heart allografts demonstrated massive lipid accumulation in the early post-indal transplant period, which probably contributed to severe intimal thickening.'04 It is, however, generally agreed that a large multicentre trial is necessary to assess the risk: benefit ratio of treating transplant recipients and thereby decreasing the incidence of cardiovascular disease. The cost and side-effects of lipidlowering agents should also be assessed in such a trial. The study of the natural history of PTHL may, however, be complicated by the fact that patients with renal failure and cholestatic liver disease may have cardiovascular co-morbidity that may be difficult to correct after transplantation.
Future directions
The ideal drug therapy for lowering serum lipids in the transplant recipient needs to be defined. A large multicentre trial will be needed to determine the optimal drug with the least side-effects, minimum drug interactions, and a positive effect on chronic allograft rejection.
The dangers of aggressive use of cholesterol-reducing agents should be balanced against the possibility of an increased incidence of psychiatric disorders and malignancies. Despite the concern about increased mortality associated with a low plasma cholesterol concentration, there was no evidence of a 'J-shaped' relationship between the total cholesterol concentration and mortality. '05
The development of immunosuppressants of maximum effectiveness with the least metabolic adverse effects should be the next goal. Novel strategies such as administration of folic acid to reduce plasma concentration of homocysteine,106
and genetic aspects of hyperlipidaemia are areas of research which may be of relevance in the treatment of PTHL.'07
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